Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Citi
Farmers Insurance
Merck
QuintilesIMS
Chinese Patent Office
US Department of Justice
Medtronic
Cipla

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ORKAMBI

« Back to Dashboard

Clinical Trials for Orkambi

Trial ID Title Status Sponsor Phase Summary
NCT02170025 Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients Recruiting Merck Sharp & Dohme Corp. Phase 2 Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi
NCT02170025 Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients Recruiting Bayer Phase 2 Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi
NCT02589236 Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation Active, not recruiting Medidata Solutions Phase 2 This will be a double-blind, randomized, placebo-controlled, parallel group study. The purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated with lumacaftor/ivacaftor (Orkambi™).
NCT02589236 Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation Active, not recruiting Nivalis Therapeutics, Inc. Phase 2 This will be a double-blind, randomized, placebo-controlled, parallel group study. The purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated with lumacaftor/ivacaftor (Orkambi™).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Orkambi

Condition Name

Condition Name for Orkambi
Intervention Trials
Cystic Fibrosis 14
Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Orkambi
Intervention Trials
Cystic Fibrosis 14
Fibrosis 12
Hyperglycemia 1
Lung Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Orkambi

Trials by Country

Trials by Country for Orkambi
Location Trials
United States 77
Germany 7
United Kingdom 3
Canada 3
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Orkambi
Location Trials
Ohio 6
Alabama 5
Florida 4
Massachusetts 4
Illinois 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Orkambi

Clinical Trial Phase

Clinical Trial Phase for Orkambi
Clinical Trial Phase Trials
Phase 3 2
Phase 2 6
N/A 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Orkambi
Clinical Trial Phase Trials
Recruiting 6
Not yet recruiting 6
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Orkambi

Sponsor Name

Sponsor Name for Orkambi
Sponsor Trials
Vertex Pharmaceuticals Incorporated 3
National Heart, Lung, and Blood Institute (NHLBI) 2
University of Miami 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Orkambi
Sponsor Trials
Other 13
Industry 8
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Federal Trade Commission
Harvard Business School
Farmers Insurance
Argus Health
Johnson and Johnson
Baxter
Accenture
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.